Top

Clinical and Translational Oncology

Published in:

01-09-2018 | Research Article

The glycosyltransferase ST6Gal-I is enriched in cancer stem-like cells in colorectal carcinoma and contributes to their chemo-resistance

Authors: H. Cui, S. Yang, Y. Jiang, C. Li, Y. Zhao, Y. Shi, Y. Hao, F. Qian, B. Tang, P. Yu

Published in: Clinical and Translational Oncology | Issue 9/2018

Abstract

Purpose

Presence of cancer stem cells (CSCs) contributes to tumor outgrowth, chemo-resistance and relapse in some cancers including colorectal carcinoma (CRC). The current characterization methods of CSCs in CRC only allows enrichment of CSCs but not their purification. Recent reports showed that ST6 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6Gal-I) plays an essential role in protecting tumor cells against harsh environment like oxidative stress and nutrient deprivation. Therefore, whether ST6Gal-I may be highly expressed in CSCs or whether it may enhance resistance of tumor cells to chemotherapy deserves exploration.

Method

ST6Gal-I levels were determined in CRC specimens, compared to paired normal colorectal tissue, and examined in CD133+ vs CD133− CRC cells, and CD44+ vs CD44− CRC cells. ST6Gal-I levels and their association with patient survival were examined. In vivo, 2 CRC cell lines Caco-2 and SW48 were transduced with two lentiviruses, one lentivirus carrying a green fluorescent protein reporter and a luciferase reporter under a cytomegalovirus promoter to allow tracing tumor cells by both fluorescence and luciferase activity, and one lentivirus carrying a nuclear red fluorescent protein under the control of ST6Gal-I promoter to allow separation of ST6Gal-I+ vs ST6Gal-I− CRC cells. Tumor sphere formation, resistance to fluorouracil-induced apoptosis, and frequency of tumor formation after serial adoptive transplantation were done on ST6Gal-I+ vs ST6Gal-I− CRC cells.

Result

ST6Gal-I levels were significantly upregulated in clinically obtained CRC specimens, compared to paired normal colorectal tissue. Poorer patient survival was detected in ST6Gal-I-high CRC, compared to ST6Gal-I-low subjects. Higher levels of ST6Gal-I were detected in CD133+ CRC cells than CD133− CRC cells, and in CD44+ CRC cells than in CD44− CRC cells. Compared to ST6Gal-I− CRC cells, ST6Gal-I+ CRC cells generated significantly more tumor spheres in culture, were more resistant to fluorouracil-induced apoptosis likely through upregulating cell autophagy, and generated tumor more frequently after serial adoptive transplantation.

Conclusion

ST6Gal-I may be highly expressed in the cancer stem-like cells in CRC and enhances cancer cell resistance to chemotherapy.

Garza-Trevino EN, Said-Fernandez SL, Martinez-Rodriguez HG. Understanding the colon cancer stem cells and perspectives on treatment. Cancer Cell Int. 2015;15(1):2. https://doi.org/10.1186/s12935-015-0163-7.CrossRefPubMedPubMedCentral

De Maio G, Zama E, Rengucci C, Calistri D. What influences preneoplastic colorectal lesion recurrence? Oncotarget. 2017;8(7):12406–16. https://doi.org/10.18632/oncotarget.13628.PubMedCrossRef

Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget. 2010;1(7):552–66. https://doi.org/10.18632/oncotarget.101016.CrossRef

Kemper K, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget. 2010;1(6):387–95. https://doi.org/10.18632/oncotarget.101003.PubMedPubMedCentralCrossRef

Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell. 2014;15(6):692–705. https://doi.org/10.1016/j.stem.2014.11.012.CrossRefPubMed

Wang T, Shigdar S, Gantier MP, Hou Y, Wang L, Li Y, et al. Cancer stem cell targeted therapy: progress amid controversies. Oncotarget. 2015;6(42):44191–206. https://doi.org/10.18632/oncotarget.6176.PubMedPubMedCentralCrossRef

Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5. https://doi.org/10.1038/nature05384.CrossRefPubMed

O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10. https://doi.org/10.1038/nature05372.CrossRefPubMed

Du L, Wang H, He L, Zhang J, Ni B, Wang X, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14(21):6751–60. https://doi.org/10.1158/1078-0432.CCR-08-1034.CrossRefPubMed

10.

Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res. 2008;68(10):3655–61. https://doi.org/10.1158/0008-5472.CAN-07-2940.CrossRefPubMed

11.

Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999;154(2):515–23. https://doi.org/10.1016/S0002-9440(10)65297-2.CrossRefPubMedPubMedCentral

12.

Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127–34. https://doi.org/10.1089/scd.2008.0338.CrossRefPubMed

13.

Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4(9):1033–43. https://doi.org/10.5966/sctm.2015-0048.CrossRefPubMedPubMedCentral

14.

Taniguchi H, Moriya C, Igarashi H, Saitoh A, Yamamoto H, Adachi Y, et al. Cancer stem cells in human gastrointestinal cancer. Cancer Sci. 2016;107(11):1556–62. https://doi.org/10.1111/cas.13069.CrossRefPubMedPubMedCentral

15.

Chen C, Ma J, Lazic A, Backovic M, Colley KJ. Formation of insoluble oligomers correlates with ST6Gal I stable localization in the golgi. J Biol Chem. 2000;275(18):13819–26.CrossRefPubMed

16.

Britain CM, Dorsett KA, Bellis SL. The glycosyltransferase ST6Gal-I protects tumor cells against serum growth factor withdrawal by enhancing survival signaling and proliferative potential. J Biol Chem. 2017;292(11):4663–73. https://doi.org/10.1074/jbc.M116.763862.CrossRefPubMedPubMedCentral

17.

Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, et al. The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res. 2016;76(13):3978–88. https://doi.org/10.1158/0008-5472.CAN-15-2834.CrossRefPubMedPubMedCentral

18.

Swindall AF, Londono-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Res. 2013;73(7):2368–78. https://doi.org/10.1158/0008-5472.CAN-12-3424.CrossRefPubMedPubMedCentral

19.

Zhang X, Pan C, Zhou L, Cai Z, Zhao S, Yu D. Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells. BMC Cancer. 2016;16(1):949. https://doi.org/10.1186/s12885-016-2981-y.CrossRefPubMedPubMedCentral

20.

Wei A, Fan B, Zhao Y, Zhang H, Wang L, Yu X, et al. ST6Gal-I overexpression facilitates prostate cancer progression via the PI3 K/Akt/GSK-3beta/beta-catenin signaling pathway. Oncotarget. 2016;7(40):65374–88. https://doi.org/10.18632/oncotarget.11699.CrossRefPubMedPubMedCentral

21.

Chen X, Wang L, Zhao Y, Yuan S, Wu Q, Zhu X, et al. ST6Gal-I modulates docetaxel sensitivity in human hepatocarcinoma cells via the p38 MAPK/caspase pathway. Oncotarget. 2016;7(32):51955–64. https://doi.org/10.18632/oncotarget.10192.PubMedPubMedCentralCrossRef

22.

Schultz MJ, Swindall AF, Wright JW, Sztul ES, Landen CN, Bellis SL. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res. 2013;6(1):25. https://doi.org/10.1186/1757-2215-6-25.CrossRefPubMedPubMedCentral

23.

Lee M, Park JJ, Ko YG, Lee YS. Cleavage of ST6Gal I by radiation-induced BACE1 inhibits golgi-anchored ST6Gal I-mediated sialylation of integrin beta1 and migration in colon cancer cells. Radiat Oncol. 2012;7:47. https://doi.org/10.1186/1748-717X-7-47.CrossRefPubMedPubMedCentral

24.

Swindall AF, Bellis SL. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem. 2011;286(26):22982–90. https://doi.org/10.1074/jbc.M110.211375.CrossRefPubMedPubMedCentral

25.

Christie DR, Shaikh FM, Lucas JAT, Lucas JA 3rd, Bellis SL. ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res. 2008;1(1):3. https://doi.org/10.1186/1757-2215-1-3.CrossRefPubMedPubMedCentral

26.

Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Mol Cancer Ther. 2009;8(5):1045–54. https://doi.org/10.1158/1535-7163.MCT-08-0717.CrossRefPubMed

27.

Srimuangwong K, Tocharus C, Yoysungnoen Chintana P, Suksamrarn A, Tocharus J. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol. 2012;18(19):2383–9. https://doi.org/10.3748/wjg.v18.i19.2383.CrossRefPubMedPubMedCentral

28.

Ayinde O, Wang Z, Griffin M. Tissue transglutaminase induces epithelial-mesenchymal-transition and the acquisition of stem cell like characteristics in colorectal cancer cells. Oncotarget. 2017;8(12):20025–41. https://doi.org/10.18632/oncotarget.15370.CrossRefPubMedPubMedCentral

29.

Saikawa Y, Fukuda K, Takahashi T, Nakamura R, Takeuchi H, Kitagawa Y. Gastric carcinogenesis and the cancer stem cell hypothesis. Gastric cancer. 2010;13(1):11–24. https://doi.org/10.1007/s10120-009-0537-4.CrossRefPubMed

30.

Samadani AA, Akhavan-Niaki H. Interaction of sonic hedgehog (SHH) pathway with cancer stem cell genes in gastric cancer. Med Oncol. 2015;32(3):48. https://doi.org/10.1007/s12032-015-0492-3.CrossRefPubMed

31.

Lu L, Wu M, Sun L, Li W, Fu W, Zhang X, et al. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: a comprehensive meta-analysis with 4729 patients involved. Medicine (Baltimore). 2016;95(42):e5163. https://doi.org/10.1097/MD.0000000000005163.CrossRefPubMedPubMedCentral

32.

Green DR, Levine B. To be or not to be? how selective autophagy and cell death govern cell fate. Cell. 2014;157(1):65–75. https://doi.org/10.1016/j.cell.2014.02.049.CrossRefPubMedPubMedCentral

33.

Jiang F. Autophagy in vascular endothelial cells. Clin Exp Pharmacol Physiol. 2016;43(11):1021–8. https://doi.org/10.1111/1440-1681.12649.CrossRefPubMed

34.

Feng Y, Yao Z, Klionsky DJ. How to control self-digestion: transcriptional, post-transcriptional, and post-translational regulation of autophagy. Trends Cell Biol. 2015;25(6):354–63. https://doi.org/10.1016/j.tcb.2015.02.002.CrossRefPubMedPubMedCentral

35.

Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571–80. https://doi.org/10.1038/cdd.2010.191.CrossRefPubMedPubMedCentral

36.

Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene. 2010;29(12):1717–9. https://doi.org/10.1038/onc.2009.519.CrossRefPubMed

37.

Oldham RA, Berinstein EM, Medin JA. Lentiviral vectors in cancer immunotherapy. Immunotherapy. 2015;7(3):271–84. https://doi.org/10.2217/imt.14.108.CrossRefPubMed

Title: The glycosyltransferase ST6Gal-I is enriched in cancer stem-like cells in colorectal carcinoma and contributes to their chemo-resistance
Authors: H. Cui
S. Yang
Y. Jiang
C. Li
Y. Zhao
Y. Shi
Y. Hao
F. Qian
B. Tang
P. Yu
Publication date: 01-09-2018
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 9/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1840-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2018

Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis

Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation

Integral nutritional approach to the care of cancer patients: results from a Delphi panel

Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients

Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

Cancer and aging in Ibero-America

Keynote webinar | Spotlight on antibody–drug conjugates in cancer